Year: 2022

Cheyenne, Wyoming, Dec. 12, 2022 (GLOBE NEWSWIRE) — Protect Pharmaceutical Corporation, Inc. (OTC:PRTT) informs, that the Share Exchange Agreement №1, signed on June 15, 2022 was not executed due to the insufficiency of legal instruments on the territory of the Republic of Belarus for conducting such transactions, and terminated on December 6, 2022. The absence of an established agreement between the US and Belarus depositories and the lack of a legal basis for conducting transactions on the international exchange of securities caused the inability to perform the obligations. According to par. 2.2-2.4 of the Agreement, the Parties shall had executed all legal obligations within 60 working days from the date of execution of the Agreement. As per September 6th, 2022 the obligations were not executed, and Parties agreed to extend...

Today, Novozymes and Chr. Hansen have entered into an agreement to create a leading global biosolutions partner through a statutory merger of the two companies. The combination is expected to unleash the full potential of biological solutions and generate significant value for all stakeholders and society at large. COPENHAGEN, Denmark – December 12, 2022. The proposed combination of Novozymes A/S (“Novozymes”) and Chr. Hansen Holding A/S (“Chr. Hansen”) will create a strong biosolutions group with a broad biological toolbox and a diversified portfolio across markets. Uniting two strategically complementary biosolutions companies will accelerate their already best-in-class performance. Novozymes and Chr. Hansen together will meet customers’ growing demands for efficient, scalable, and sustainable biosolutions. The...

EXOR N.V. (AMS: EXO) (“Exor” or the “Company”) announces that, under the second tranche of the share buyback program of up to €250 million announced on 29 July 2022 (the “second tranche”), the Company has completed the following transactions on Euronext Amsterdam:Trading Date Number of ordinary shares purchased Average price per share excluding fees (€) Total consideration excluding fees (€)5 December 2022 26,850 76.4480 2,052,628.806 December 2022 38,046 76.1888 2,898,679.087 December 2022 36,088 74.6917 2,695,474.078 December 2022 39,624 74.0543 2,934,327.589 December 2022 22,973 73.9245 1,698,267.54TOTAL 163,581   12,279,377.07After these purchases, the total invested amount under the second tranche is approximately €128.9 million for a total amount of 1,930,000 ordinary shares purchased. As of 9 December 2022,...

ANNOUNCEMENT A.P. Møller – Mærsk A/S – Change of CEO Effective as of 1 January 2023 Vincent Clerc will be appointed new CEO of A.P. Møller – Mærsk A/S replacing Søren Skou who will leave the Group. Vincent Clerc is currently CEO of Ocean & Logistics and has been with the Group for 25 years. The Executive Board will hereafter consist of CEO Vincent Clerc, CFO Patrick Jany, Henriette Hallberg Thygesen and Navneet Kapoor. Copenhagen, 12 December 2022 Contact persons: Head of Investor Relations, Sarah Spray, tel. +45 3363 3106 Head of Media Relations, Jesper Løv, tel. +45 6114 1521 Page 1 of 1AttachmentAnnouncement – Change of CEO

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR  Asset impairment of approximately CHF 225 million relating to Clariant’s bioethanol plant in Podari, Romania Planned commercialization and optimization process of the plant continue with the aim to industrialize the sunliquid® technology Clariant confirms the unique value of its second-generation bio-based cellulosic ethanol solutionsMUTTENZ, DECEMBER 12, 2022 Clariant, a focused, sustainable, and innovative specialty chemical company, today announced a financial impairment of its sunliquid® plant in Podari, Romania, amounting to approximately CHF 225 million. As previously reported, the sunliquid® plant began production in the second quarter of 2022, though has not yet achieved the targeted yields and other operational parameters on an industrial scale. Clariant has thus completed a financial...